Special Issue "Drug Candidates for the Treatment of Tuberculosis 2021"
Deadline for manuscript submissions: 15 July 2022.
Interests: bioorganic chemistry, chemical biology; drug design; enzyme inhibitors; antitubercular agents; InhA, tuberculosis
Special Issues, Collections and Topics in MDPI journals
Tuberculosis (TB) is a scourge and the leading cause from a single infectious agent worldwide. In 2018, 1.5 million TB deaths including about 300,000 deaths among HIVpositive people were estimated. The emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Mycobacterium tuberculosis (Mtb) strains has exacerbated the situation. Effective drug treatments were first developed in the 1940s. Isoniazid, pyrazinamide, ethambutol and rifampicin, considered as first-line drugs, were used for tuberculosis chemotherapy for years. During 50 years, no antituberculosis drug has been found. However, drugs such as bedaquiline, delamanid and pretomanid appeared recently as new antitubercular agents for the treatment of drug-resistance-TB. Even if in recent years, considerable efforts have been made in developing a TB drug pipeline, there is an urgent need to discover new drugs to combat existing drug-resistance and accelerate eradication of TB forever.
This special issue “Drug Candidates for the Treatment of Tuberculosis 2021” in Pharmaceuticals aims to provide the opportunity to share new findings and progress of research into new anti-tuberculosis drugs. Topics will include drug design, protein inhibitors, high throughput screening, hit generation, lead optimization and modification, drug mechanism, drug candidate. Contributions in other topics will be also considered. Both research articles and reviews in this field are welcome. Dr. Christian LherbetGuest editor
Dr. Christian Lherbet
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- drug candidates
- enzyme inhibitors
- medicinal chemistry